Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.

How does the micro-cap biotech now finance a 700-patient phase 3 study?

A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.

Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.

Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.

The first-line liver cancer Emerald-1 trial is positive, but only up to a point.

The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.

The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.